Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PBYI
stocks logo

PBYI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
68.60M
+16.07%
0.193
-50.64%
49.00M
+6.52%
0.000
-100%
55.00M
+4.96%
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Puma Biotechnology, Inc. (PBYI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 5.17%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+5.17%
In Past 3 Month
Wall Street analysts forecast PBYI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBYI is 3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast PBYI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBYI is 3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 5.290
sliders
Low
2.00
Averages
3.50
High
5.00
Current: 5.290
sliders
Low
2.00
Averages
3.50
High
5.00
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$7
2025-02-28
Reason
HC Wainwright & Co.
Edward White
Price Target
$7
2025-02-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$7
2024-12-23
Reason
HC Wainwright & Co.
Edward White
Price Target
$7
2024-12-23
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Puma Biotechnology Inc (PBYI.O) is 11.16, compared to its 5-year average forward P/E of -74.35. For a more detailed relative valuation and DCF analysis to assess Puma Biotechnology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-74.35
Current PE
11.16
Overvalued PE
252.69
Undervalued PE
-401.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
5.89
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
15.27
Undervalued EV/EBITDA
-3.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.88
Current PS
0.00
Overvalued PS
1.26
Undervalued PS
0.50
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 203.1% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PBYI News & Events

Events Timeline

(ET)
2025-11-06
16:39:46
Puma Biotechnology announces Q3 EPS of 21 cents, surpassing estimate of 9 cents
select
2025-11-06
16:39:10
Puma Biotechnology announces quarterly EPS of 21 cents, surpassing estimate of 9 cents.
select
2025-05-08 (ET)
2025-05-08
16:24:29
Puma Biotechnology reports Q1 EPS 10c, two estimates 3c
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03Businesswire
Puma Biotechnology Grants 3,500 Restricted Stock Units to New Employee
  • Stock Award Plan: On December 1, 2025, Puma Biotechnology approved the grant of 3,500 restricted stock units to a new non-executive employee, aimed at attracting talent and enhancing employee loyalty.
  • Vesting Conditions: The stock units will vest over three years, with one-third unlocking in the first year and one-sixth every six months thereafter, ensuring continued service for full benefits.
  • Incentive Mechanism: This award is granted under Puma's 2017 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), designed to attract and retain key talent through equity incentives.
  • Corporate Strategy: By implementing such incentive measures, Puma not only boosts employee motivation but also strengthens its market position in the highly competitive biopharmaceutical industry.
[object Object]
Preview
3.0
11-28NASDAQ.COM
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Superior Choice?

  • Ironwood Pharmaceuticals Overview: Ironwood focuses on gastrointestinal disorders with its sole marketed drug, Linzess, which has seen significant sales growth, leading to an optimistic revenue outlook for 2025. The company is also developing apraglutide for short bowel syndrome, although it remains heavily reliant on Linzess for revenue.

  • Puma Biotechnology Overview: Puma Biotechnology specializes in cancer treatments, particularly with its drug Nerlynx for breast cancer, which has shown modest sales growth. However, the company faces risks due to its dependence on a single product and competition in the crowded breast cancer market.

  • Investment Comparison: Analysts suggest that Ironwood may be a better investment opportunity compared to Puma Biotechnology, given its steady earnings momentum and positive growth outlook, despite Ironwood's higher price-to-sales ratio.

  • Market Performance: Year-to-date, Ironwood's shares have declined while Puma's have surged, reflecting differing market perceptions. Ironwood's strong revenue guidance and rising earnings estimates contrast with Puma's vulnerability to regulatory and competitive challenges.

[object Object]
Preview
4.0
11-11NASDAQ.COM
Daily Upgrade Report for Validea Kenneth Fisher Strategy - November 11, 2025

  • Validea's Upgrades: Today's upgrades for Validea's Price/Sales Investor model highlight ARRAY Digital Infrastructure Inc. and Puma Biotechnology Inc., with ratings improving significantly based on their fundamentals and valuations.

  • ARRAY Digital Infrastructure Inc.: This mid-cap growth stock in the Communications Services industry has seen its rating rise from 50% to 70%, indicating a positive outlook due to its extensive wireless infrastructure and potential in 5G deployment.

  • Puma Biotechnology Inc.: A small-cap value stock in the Biotechnology & Drugs sector, Puma's rating increased from 50% to 80%, reflecting strong fundamentals and its focus on cancer care products, particularly NERLYNX for HER2-positive breast cancers.

  • About Kenneth Fisher and Validea: Kenneth Fisher, a prominent money manager and author, is known for his investment strategies, including the use of price/sales ratios. Validea provides investment research based on the strategies of successful investors like Fisher, aiming to help investors identify attractive stocks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Puma Biotechnology Inc (PBYI) stock price today?

The current price of PBYI is 5.29 USD — it has increased 1.93 % in the last trading day.

arrow icon

What is Puma Biotechnology Inc (PBYI)'s business?

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.

arrow icon

What is the price predicton of PBYI Stock?

Wall Street analysts forecast PBYI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBYI is 3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Puma Biotechnology Inc (PBYI)'s revenue for the last quarter?

Puma Biotechnology Inc revenue for the last quarter amounts to 54.48M USD, decreased -32.36 % YoY.

arrow icon

What is Puma Biotechnology Inc (PBYI)'s earnings per share (EPS) for the last quarter?

Puma Biotechnology Inc. EPS for the last quarter amounts to 0.17 USD, decreased -58.54 % YoY.

arrow icon

What changes have occurred in the market's expectations for Puma Biotechnology Inc (PBYI)'s fundamentals?

The market is revising No Change the revenue expectations for Puma Biotechnology, Inc. (PBYI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 5.17%.
arrow icon

How many employees does Puma Biotechnology Inc (PBYI). have?

Puma Biotechnology Inc (PBYI) has 172 emplpoyees as of December 05 2025.

arrow icon

What is Puma Biotechnology Inc (PBYI) market cap?

Today PBYI has the market capitalization of 266.32M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free